


Vasoplegic shock in intensive care medicine

CytoSorb Therapy - REGAIN CONTROL



With CytoSorb you can pursue these targets:

(supported by clinical and preclinical * data)

- Stabilization in hemodynamics ^(4,5,6,15)
- Promotion of capillary integrity ⁽⁷⁾
- Regulation of fluid balance ^(4,5,6)
- Improvement in outcome ^(5,6,13,15,17)





Regain control in shock



If standard therapy based on guidelines fails to give sufficient hemodynamic stabilization, CytoSorb should be considered as an adjunctive therapy.

▼ Study results



Out of 20 patients in refractory septic shock with high levels of norepinephrine, shock reversal was achieved in 13 patients after start of CytoSorb therapy.⁽⁶⁾

▼ Early reduction of high vasopressor levels as major target

- Vasopressor therapy is a cornerstone of standard therapy of vasoplegic shock. However, high levels are associated with poor outcome.⁽¹⁶⁾
- CytoSorb therapy aims at hemodynamic stabilization and rapid reduction of vasopressor needs and improved outcome.⁽¹⁷⁾

References (* preclinical data):

- Kellum JA et al. Crit Care Med. 2004 Mar;32(3): 801-5 *
- Kellum JA et al. Crit Care Med. 2008 Jan;36(1): 268-7 *
- Linden K et al. Shock 2015 Nov; 44(5): 487-95. *
- Traeger K et al. Int J Artif Organs 2016 May 16;39(3): 141-6
- Kogelmann K et al. Crit Care 2017 Mar; 21: 74
- Friesecke S et al. Journal Artif Organs 2017; 20(3): 252-9
- David S et al. J Intensive Care 2017; 5: 12
- Faenza S et al. Crit Care 2016, 20(Suppl 2): P192 *
- Buttner S et al. Blood Purif 2017 44(1): 30-31
- Kuntsevich V. I. et al. Artif Cells Blood Substit Biotechnol 2009, 37(1): 45-7 *
- Gruda M et al. PLoS One 2018; 13(1):e0191676 *
- Venkataraman R et al. Blood Purif 2004; 22: 143-149 *
- Friesecke S et al. Med Klin Intensivmed Notfmed 2017 Sep 4
- Schaedler D et al. PLoS One 2017, 12(10) epub
- Kogelmann, K et al. JICS 2019: epub
- Auchet T et al. Ann. Intensive Care 2017; 7:43
- Brouwer WP et al. Crit Care 2019 23:317

Visit <http://literature.cytosorb.com> for an overview of all references

CytoSorbents Europe GmbH

Müggelseedamm 131
12587 Berlin | Germany
T +49 30 65 49 91 45
F +49 30 65 49 91 46
support@cytosorbents.com

CytoSorbents Switzerland GmbH

c/o MGM GmbH
Wielandstrasse 5 | 4153 Reinach BL | Switzerland
T +41 61 713 73 78
F +41 61 713 73 79
support@cytosorbents.com

www.cytosorb.com

The clinical and preclinical data and results obtained with the CytoSorb adsorber are not transferable to other products. CytoSorb should only be administered by personnel who have been properly trained in administration of extracorporeal therapies.

CytoSorb is not available for commercial sale in USA. CytoSorb and CytoSorbents are trademarks of the CytoSorbents Corporation, USA. © Copyright 2019, CytoSorbents Europe GmbH. All rights reserved. B1001R05EN2019